Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Everest Medicines Limited
雲頂新耀有限公司
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 1952)

POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON TUESDAY, 24 FEBRUARY 2026

Reference is made to the circular (the "**Circular**") of Everest Medicines Limited (the "**Company**") incorporating, amongst others, the notice (the "**Notice**") of the extraordinary general meeting of the Company (the "**EGM**") dated 4 February 2026. Unless the context requires otherwise, the capitalized terms used herein shall have the same meanings as those defined in the Circular.

On 24 February 2026, the EGM was held by way of virtual meeting via the Online Platform and all the proposed resolutions as set out in the Notice were duly passed by the Shareholders by way of poll. The poll results in respect of the resolutions proposed at the EGM are as follows:

Ordinary Resolutions		**Number of Votes (%)**	
		For	**Against**
1.	To approve, confirm and ratify the Commercialization Service Agreement and the transactions contemplated thereunder.	55,142,382 (99.88%)	65,500 (0.12%)
2.	To approve and confirm the grant of 530,303 awards to Mr. Yifang Wu in accordance with the terms of the Pre-IPO ESOP.	129,440,001 (92.44%)	10,579,260 (7.56%)

Ordinary Resolutions		Number of Votes (%)	
		For	Against
3.	To approve and adopt the 2026 Share Scheme with the Scheme Mandate Limit (as defined in the 2026 Share Scheme) of 10% of the total issued and outstanding Shares (excluding any treasury shares) as at the date of the Shareholders' approval of the 2026 Share Scheme, and to authorize the Board and the Scheme Administrator (as defined in the 2026 Share Scheme) to grant the awards and do all such acts and execute all such documents as the Board or the Scheme Administrator may consider necessary or expedient in order to give full effect to the 2026 Share Scheme.	129,708,549 (92.69%)	10,234,260 (7.31%)
4.	Conditional upon the passing of ordinary resolution 3, to approve and adopt the Service Provider Sublimit (as defined in the 2026 Share Scheme, and which includes grants to Service Provider Participants under any other share schemes of the Company) of 0.5% of the total issued and outstanding Shares (excluding any treasury shares) as at the date of the Shareholders' approval of the 2026 Share Scheme.	129,825,049 (92.73%)	10,184,260 (7.27%)

Notes:

(a) As a majority of the votes were cast in favour of each of the resolutions numbered 1 to 4, such resolutions were duly passed as ordinary resolutions of the Company. The full text of the aforesaid resolutions is set out in the Circular.

(b) As at the date of the EGM, (i) the total number of Shares in issue was 353,581,158 Shares; and (ii) there were no treasury Shares held by the Company (including any treasury Shares held or deposited with CCASS). Accordingly, the total number of Shares entitling the holders to attend and vote for or against the resolutions proposed at the EGM was 353,581,158 Shares.

(c) The trustees holding unvested Shares awarded under the Company's share schemes held 2,096,219 Shares as at the date of the EGM and were required under Rule 17.05A of the Listing Rules to abstain from voting on matters that require Shareholders' approval under the Listing Rules.

(d) As at the date of the EGM, to the best of the Directors' knowledge, information and belief having made all reasonable enquiry, Mr. Wei Fu and CBC Group, and Mr. Yifang Wu were interested in 85,222,427 and 307,000 Shares held by him (and his associates), respectively and options for which no voting rights may be exercisable. Mr. Wei Fu and CBC Group (and their associates) were required to abstain from voting on the resolution numbered 1; and Mr. Yifang Wu (and his associates) were required to abstain from voting on the resolution numbered 2.

(e) Save as mentioned above, no shareholder of the Company was required under the Listing Rules to abstain from voting on the resolutions at the EGM and there were no Shares entitling the holder to attend and abstain from voting in favour as set out in Rule 13.40 of the Listing Rules.

(f) None of the shareholders of the Company have stated their intention in the Circular to vote against or to abstain from voting on any of the resolutions at the EGM.

(g) The Company's Hong Kong share registrar, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the vote-taking at the EGM.

(h) The EGM was chaired by Mr. Yifang Wu, and Mr. Wei Fu, Mr. Yongqing Luo, Mr. Ian Ying Woo, Mr. William Ki Chul Cho, Mr. Xin Sun, Ms. Hoi Yam Chui, Mr. Yifan Li and Mr. Shidong Jiang attended the EGM.

By order of the Board
Everest Medicines Limited
Yifang Wu
Chairman and Executive Director

Hong Kong, 24 February 2026

As at the date of this announcement, the Board comprises Mr. Yifang Wu as Chairman and Executive Director, Mr. Yongqing Luo and Mr. Ian Ying Woo as Executive Directors, Mr. Wei Fu, Mr. William Ki Chul Cho and Mr. Xin Sun as Non-executive Directors, and Ms. Hoi Yam Chui, Mr. Yifan Li and Mr. Shidong Jiang as Independent Non-executive Directors.